Animal StudyPubMed ID: 38265347·2024

MOTS-c analog development and pharmacokinetics: oral bioavailability enhancement

Mnatsakanyan VV, Sripada L, Ye Q, et al.

Biochemical Pharmacology, 2024

Key finding

Lead analog showed 8-fold improved oral bioavailability (15% vs 1.9% for native MOTS-c) and maintained metabolic benefits at 5mg/kg oral dose.

Summary

Development of MOTS-c analogs with improved stability and oral bioavailability, testing in mice with pharmacokinetic and tissue distribution studies.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

MOTS-cL2

A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.

More research on MOTS-c

Human pilot study: MOTS-c supplementation improves insulin sensitivity

Journal of Clinical Endocrinology & Metabolism · 2025 · Human Pilot

Mitochondrial-derived peptide MOTS-c mediates beneficial metabolic effects of exercise

Cell Reports · 2024 · Animal Study

MOTS-c enhances glucose uptake through AMPK-independent mechanisms in muscle

Metabolism: Clinical & Experimental · 2024 · Animal Study

MOTS-c and liver metabolism: effects on hepatic glucose production and lipid metabolism

Journal of Hepatology · 2024 · Animal Study

MOTS-c cross-reactivity with other GPCR signaling: pharmacological profiling

Journal of Pharmacology and Experimental Therapeutics · 2024 · In Vitro